These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36938775)

  • 1. Management of noncytotoxic extravasation injuries: A focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline.
    Stefanos SS; Kiser TH; MacLaren R; Mueller SW; Reynolds PM
    Pharmacotherapy; 2023 Apr; 43(4):321-337. PubMed ID: 36938775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of extravasation injuries: a focused evaluation of noncytotoxic medications.
    Reynolds PM; MacLaren R; Mueller SW; Fish DN; Kiser TH
    Pharmacotherapy; 2014 Jun; 34(6):617-32. PubMed ID: 24420913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extravasation of Noncytotoxic Drugs: A Review of the Literature.
    Le A; Patel S
    Ann Pharmacother; 2014 Jul; 48(7):870-886. PubMed ID: 24714850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of extravasation and local tissue injury from administration of vasopressors through peripheral intravenous catheters and central venous catheters.
    Loubani OM; Green RS
    J Crit Care; 2015 Jun; 30(3):653.e9-17. PubMed ID: 25669592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Risk of Injury by Extravasation of Hyperosmolar and Vasopressor Agents in a Rat Model.
    Shibata Y; Sagara Y; Yokooji T; Taogoshi T; Tanaka M; Hide M; Matsuo H
    Biol Pharm Bull; 2018; 41(6):951-956. PubMed ID: 29863084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for Management of Noncytotoxic Vesicant Extravasations.
    Ong J; Van Gerpen R
    J Infus Nurs; 2020; 43(6):319-343. PubMed ID: 33141794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extravasation of Noncytotoxic Drugs.
    David V; Christou N; Etienne P; Almeida M; Roux A; Taibi A; Mathonnet M
    Ann Pharmacother; 2020 Aug; 54(8):804-814. PubMed ID: 32054312
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of the Peripheral Administration of Vasopressor Agents.
    Lewis T; Merchan C; Altshuler D; Papadopoulos J
    J Intensive Care Med; 2019 Jan; 34(1):26-33. PubMed ID: 28073314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extravasation injuries: a review.
    Goutos I; Cogswell LK; Giele H
    J Hand Surg Eur Vol; 2014 Oct; 39(8):808-18. PubMed ID: 24401738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.
    Schroth M; Plank C; Meissner U; Eberle KP; Weyand M; Cesnjevar R; Dötsch J; Rascher W
    Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-Term Peripheral Vasoactive Infusions in Pediatrics: Where Is the Harm?
    Patregnani JT; Sochet AA; Klugman D
    Pediatr Crit Care Med; 2017 Aug; 18(8):e378-e381. PubMed ID: 28617763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Extravasation of chemotherapeutic agents: prevention and therapy].
    Jordan K; Grothe W; Schmoll HJ
    Dtsch Med Wochenschr; 2005 Jan; 130(1-2):33-7. PubMed ID: 15619172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extravasation of chemotherapeutic agents: prevention and treatment.
    Goolsby TV; Lombardo FA
    Semin Oncol; 2006 Feb; 33(1):139-43. PubMed ID: 16473651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extravasation of Noncytotoxic Agents: Skin Injury and Risk Classification.
    Shibata Y; Taogoshi T; Matsuo H
    Biol Pharm Bull; 2023; 46(6):746-755. PubMed ID: 37258139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extravasation management.
    Schulmeister L
    Semin Oncol Nurs; 2007 Aug; 23(3):184-90. PubMed ID: 17693345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of peripheral administration of vasopressor medications: A systematic review.
    Tian DH; Smyth C; Keijzers G; Macdonald SP; Peake S; Udy A; Delaney A
    Emerg Med Australas; 2020 Apr; 32(2):220-227. PubMed ID: 31698544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of a neonatal peripheral intravenous infiltration/extravasation (PIVIE) injury with hyaluronidase: a case report.
    van Rens M; Hugill K; Francia AL; Abdelwahab AH; Garcia KL
    Br J Nurs; 2022 Apr; 31(8):S31-S36. PubMed ID: 35439074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, risk factors and treatment outcomes of drug extravasation in pediatric patients in China.
    Yan YM; Gong M; Chen JL; Li D; Xu TT; Zou H; Li AQ; Fan QL; Lu QF
    Turk J Pediatr; 2017; 59(2):1621-168. PubMed ID: 29276869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyaluronidase for the management of dextrose extravasation.
    Wiegand R; Brown J
    Am J Emerg Med; 2010 Feb; 28(2):257.e1-2. PubMed ID: 20159411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin necrosis from intravenously infused materials.
    Dufresne RG
    Cutis; 1987 Mar; 39(3):197-8. PubMed ID: 3829727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.